Kidney transplant study aims to find safer drug combo
NCT ID NCT06374095
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at 75 kidney transplant patients to compare two different drug combinations given right after transplant. One group gets a single dose of RATG plus basiliximab, while the other gets seven doses of RATG plus basiliximab. The goal is to see which approach causes fewer side effects like low platelet or white blood cell counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Basiliximab and RATG (Thymoglobulin)
What this could lead to
If successful, this could help doctors choose a safer drug combination for kidney transplant patients, reducing side effects like low blood cell counts.
What could go wrong
This is a small, observational study with only 75 patients, so results may not apply to everyone. It compares existing drugs, not a new breakthrough.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, 24127, Italy